• AR Heterogeneity and Enzalutamide Response in CRPC

  2026-10-07

  Li and colleagues show that heterogeneous androgen receptor expression marks biologically distinct castration-resistant prostate cancer states with different responses to castration and enzalutamide. By combining patient-tissue analysis, engineered cell models, xenografts, transcriptomics, and therapeutic experiments, the study identifies BCL-2 as a candidate vulnerability while defining important limits for AR-targeted treatment strategies.

• BCS Biowaiver Evidence for Taltirelin ODTs

  2026-10-07

  Ono and Sugano examined whether dissolution evidence could support bioequivalence decisions for orally disintegrating tablets and immediate-release products containing BCS class III drugs, including Taltirelin. Their results support extending the BCS biowaiver concept to selected ODT–IR comparisons while showing that dissolution-profile differences do not always predict clinical inequivalence.

• Patient-Derived Gastric Cancer Assembloids Explained

  2026-10-06

  Shapira-Netanelov and colleagues developed a patient-derived gastric cancer assembloid model that combines matched tumor organoids with stromal cell subpopulations from the same tumor tissue. The study shows that stromal context changes gene expression and drug sensitivity, supporting more physiologically relevant investigation of tumor–stroma interactions and treatment resistance.

• ROS-Responsive Lipid Nanoparticles for Tumor-Selective mRNA

  2026-10-06

  The reference study reports a combinatorial library of ROS-degradable lipids designed to preferentially release mRNA in tumor cells. Its lead formulation, BAmP-TK-12, supported tumor-selective delivery of mRNA encoding the RAS protease DUF5 and produced stronger preclinical antitumor effects than the small-molecule comparator used in the study.

• Lopinavir (ABT-378): Evidence Beyond HIV

  2026-10-05

  A source-grounded overview of Lopinavir and ABT-378 in HIV research and coronavirus repurposing, emphasizing the distinction between biochemical potency, cell-culture findings, translational relevance, and evidence limitations.

• Anlotinib and Multi-Target Angiogenesis Inhibition

  2026-10-05

  The 2018 Gene study identified anlotinib as a multi-target tyrosine kinase inhibitor that suppresses angiogenic signaling through VEGFR2, PDGFRβ, and FGFR1. Its combination of endothelial migration, tube formation, ex vivo vessel-sprouting, and signaling evidence supports a multi-pathway anti-angiogenic mechanism, while remaining preclinical and assay-context dependent.

• Mitochondrial IRF3 in Pulmonary Fibrosis

  2026-10-04

  A 2026 Cellular Signalling study identifies mitochondrial IRF3 as a mechanistic link between cGAS-STING activation, impaired mitophagy, and ferroptosis in pulmonary fibrosis. The findings support IRF3 mitochondrial translocation as a research target, while the mouse and A549-cell evidence remains preclinical and model-dependent.

• Anlotinib Hydrochloride: Evidence and Research Context

  2026-10-03

  An evidence-focused overview of Anlotinib hydrochloride as a multi-target tyrosine kinase inhibitor, covering its anti-angiogenic rationale, supplier-reported laboratory findings, a published desmoplastic small round cell tumor case, evidence strength, translational relevance, and key limitations.

• Epinephrine Bitartrate: Designing Better Assays

  2026-10-02

  Epinephrine Bitartrate is a non-selective adrenergic receptor agonist with applications spanning receptor pharmacology, cardiovascular disease research, and translational pharmacokinetics. This guide shows how to convert receptor potency, time-resolved exposure, and heart-rate data into more reproducible experimental designs.

• PPP1R3G/PP1γ Control RIPK1 Cell Death

  2026-10-01

  The reference study identifies PPP1R3G as the regulatory subunit that recruits PP1γ to TNFR1 complex I, enabling removal of inhibitory RIPK1 phosphorylation and promoting RIPK1-dependent apoptosis and type I necroptosis. Its combination of sensitized CRISPR screening, genetic rescue, phosphorylation-site epistasis, and mouse genetics defines a mechanistic link between phosphatase recruitment, inflammatory signaling, and cell-death execution.

• Anlotinib Hydrochloride: From Kinase Maps to Translation

  2026-10-01

  Anlotinib hydrochloride offers a mechanistically coherent way to study tumor angiogenesis by simultaneously suppressing VEGFR2, PDGFRβ, FGFR1, and downstream ERK signaling. This thought-leadership guide translates evidence from endothelial assays and in vivo angiogenesis models into practical strategies for assay design, competitive benchmarking, pharmacokinetic interpretation, and translational cancer research.

• Olive Biophenols in Alzheimer’s Disease Models

  2026-09-30

  The reference study connects direct anti-amyloid activity in SH-SY5Y cells with reduced plaque deposition in APPswe/PS1dE9 mice. Its main contribution is a translational design that tests olive biophenols under conventional, metal-associated, and L-DOPA-associated amyloid toxicity conditions while identifying oleuropein, verbascoside, and rutin as leading candidates.

• MK 0893: Glucagon Receptor Antagonist Workflows

  2026-09-30

  Build reproducible GCGR binding and cAMP assays with MK 0893, then connect receptor pharmacology to glucose excursion reduction in hGCGR mice. This guide emphasizes solvent control, concentration-response design, selectivity testing, and practical troubleshooting for type 2 diabetes research.

• From RNase Control to mRNA Vaccine Translation

  2026-09-29

  A translational perspective on how RNA integrity, particle charge, formulation simplicity, and quality control can determine the path from cationic liposome research to personalized mRNA cancer vaccines.

• Quizartinib (AC220) FLT3 Research Workflows

  2026-09-29

  Quizartinib (AC220) combines nanomolar FLT3 potency with strong kinase selectivity, making it useful for separating FLT3-driven signaling from downstream resistance biology. This workflow-focused guide covers phospho-FLT3 assays, AML cell viability studies, resistance modeling, and carefully bounded translation to FLT3-positive blast-phase CML research.

8177 records 1/546 page Next 12345 下5页 Last page